Silver North Resources Ltd. press release

DEADLINE APPROACHING: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors to Inquire About a Securities Fraud Class Action by July 22, 2025

2025-07-10

TSXV - TSX Venture Exchange · Silver · Gold · Lead · Zinc · Copper · Canada

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the “Class Period”).

_Investor Deadline: Investors who purchased or acquired _Organon _securities during the Class Period may, no later than JULY 22, 2025 , seek to be appointed as a lead plaintiff representative of the class. __To learn your rights, __CLICK HERE __. _

Organon, headquartered in Jersey City, NJ, is a healthcare company focused on women’s health. In October 2024, Organon acquired Dermavant, a biopharmaceutical company focused on dermatological conditions, for $1.2 billion.

According to the lawsuit, despite the increase in debt from the Dermavant acquisition, the Company assured investors that it would maintain its dividend, which it described as its “#1 capital allocation priority.” The suit alleges that, notwithstanding such representations, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt.

In addition, the lawsuit alleges that defendants failed to disclose that Organon faced a higher risk of loss of exclusivity and price erosion as to Nexplanon. Thus, Nexplanon sales growth was not as strong as defendants represented and would not reach $1 billion by the end of fiscal year 2025. As a result, Organon was likely not on track to achieve the $1 billion milestone payment from Merck & Co. on its Nexplanon sales.

On May 1, 2025, investors learned the truth when Organon announced that management reset the Company’s dividend payout from $0.28 per share to $0.02 per share. Organon’s senior management explained that the Company had “reset our capital allocation priorities to accelerate progress towards deleveraging” and that “returning capital to shareholders is right now, less of a priority.”

On this news, the price of Organon stock declined $3.48 per share – approximately 27% – from a closing price of $12.93 per share on April 30, 2025 to a close of $9.45 per share on May 1, 2025.

_To learn your rights or for more information, __CLICK HERE __or please contact Berger Montague: Andrew Abramowitz at __aabramowitz@bm.net __or (215) 875-3015, or Caitlin Adorni at __cadorni@bergermontague.com __or (267)764-4865. _

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contact:

Andrew Abramowitz, Senior Counsel Berger Montague (215) 875-3015 aabramowitz@bergermontague.com

Caitlin Adorni Berger Montague (267) 764-4865 cadorni@bergermontague.com

[](https://www.globenewswire.com/NewsRoom/AttachmentNg/fea62df2-245b-43bd-b9e5-9ddaca23f74d)